search
Back to results

Comparison Between Infant Flow SiPAP and Noninvasive NAVA in the Neonatal Intensive Care Unit

Primary Purpose

Respiratory Distress Syndrome

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Neurally Adjusted Ventilatory Assist (NAVA)
SiPAP - placebo
Sponsored by
Fraser Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Respiratory Distress Syndrome

Eligibility Criteria

28 Weeks - 32 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Infants born greater than or equal to 28+0 weeks and less than or equal to 31+6 weeks gestation
  • Diagnosis of RDS in the first 24 hours of life requiring respiratory support
  • Parental consent obtained

Exclusion Criteria:

  • Infants with a major congenital anomaly
  • Infants with pulmonary hypoplasia
  • Infants known or suspected to have a neuromuscular disorder
  • Infants less than 28+0 weeks GA
  • Intubated infants that are likely to require continued mechanical ventilation
  • Infants requiring vigorous resuscitation at birth, including chest compressions +/- cardiac medications

Sites / Locations

  • Surrey Memorial Hospital
  • Surrey Memorial Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

SiPAP

Neurally Adjusted Ventilatory Assist

Arm Description

Outcomes

Primary Outcome Measures

total duration of respiratory support which includes both days and hours on NAVA/SiPAP (DORS)

Secondary Outcome Measures

Proportion of infants that required escalation to increased noninvasive respiratory support (BiPhasic or increasing NAVA levels) or intubation and mechanical ventilation
All cause mortality during the hospitalization
Bronchopulmonary dysplasia defined as oxygen requirements or ventilatory support needs at 36 weeks CGA
Number of doses of surfactant
Incidence of pneumothorax
Total duration of oxygen requirement
Incidence of nasal deformities, specifically nasal erosions
Time to reach full volume feeds (at least 120 ml/kg/day)
Time to regain birth weight
Total length of hospital stay

Full Information

First Posted
April 26, 2012
Last Updated
May 25, 2015
Sponsor
Fraser Health
search

1. Study Identification

Unique Protocol Identification Number
NCT01588080
Brief Title
Comparison Between Infant Flow SiPAP and Noninvasive NAVA in the Neonatal Intensive Care Unit
Official Title
A Pilot Study Comparing Infant Flow SiPAP to Noninvasive NAVA
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Completed
Study Start Date
July 2012 (undefined)
Primary Completion Date
November 2014 (Actual)
Study Completion Date
November 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fraser Health

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
When babies are born premature, they often need help with their breathing. The equipment used to help them breathe is not very comfortable and they sometimes need to be put on a specialized breathing machine with a tube into their lungs. The breathing machine or ventilator can be damaging to the newborn's lungs and more damage can occur the longer the newborn stays on a ventilator leading to chronic lung disease later in their lives. A new device called neurally adjusted ventilatory assist or NAVA is available that the investigators believe may be more comfortable for the premature newborn and may help the baby come off breathing support sooner. When using this device, babies may not need to be put on a ventilator and can avoid the lung damage associated with the breathing tube and the ventilator. The objective of this pilot study is to compare this new breathing device called NAVA, to the equipment that is currently being used, called SiPAP, to support premature newborn's breathing after birth without a breathing tube. The investigators hope to show that with this new technology, premature newborns that are having a difficult time breathing, will come off breathing support sooner compared to the breathing machines that are currently being used. The hypothesis for this proposed study is that improved synchrony with noninvasive NAVA will decrease time spent on noninvasive ventilation and avoid intubation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Distress Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
21 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SiPAP
Arm Type
Placebo Comparator
Arm Title
Neurally Adjusted Ventilatory Assist
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Neurally Adjusted Ventilatory Assist (NAVA)
Intervention Description
Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
Intervention Type
Device
Intervention Name(s)
SiPAP - placebo
Intervention Description
The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
Primary Outcome Measure Information:
Title
total duration of respiratory support which includes both days and hours on NAVA/SiPAP (DORS)
Time Frame
one year
Secondary Outcome Measure Information:
Title
Proportion of infants that required escalation to increased noninvasive respiratory support (BiPhasic or increasing NAVA levels) or intubation and mechanical ventilation
Time Frame
one year
Title
All cause mortality during the hospitalization
Time Frame
one year
Title
Bronchopulmonary dysplasia defined as oxygen requirements or ventilatory support needs at 36 weeks CGA
Time Frame
one year
Title
Number of doses of surfactant
Time Frame
one year
Title
Incidence of pneumothorax
Time Frame
one year
Title
Total duration of oxygen requirement
Time Frame
one year
Title
Incidence of nasal deformities, specifically nasal erosions
Time Frame
one year
Title
Time to reach full volume feeds (at least 120 ml/kg/day)
Time Frame
one year
Title
Time to regain birth weight
Time Frame
one year
Title
Total length of hospital stay
Time Frame
one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
28 Weeks
Maximum Age & Unit of Time
32 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Infants born greater than or equal to 28+0 weeks and less than or equal to 31+6 weeks gestation Diagnosis of RDS in the first 24 hours of life requiring respiratory support Parental consent obtained Exclusion Criteria: Infants with a major congenital anomaly Infants with pulmonary hypoplasia Infants known or suspected to have a neuromuscular disorder Infants less than 28+0 weeks GA Intubated infants that are likely to require continued mechanical ventilation Infants requiring vigorous resuscitation at birth, including chest compressions +/- cardiac medications
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ravinder Kajla
Organizational Affiliation
Fraser Health
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rebecca Sherlock, MD
Organizational Affiliation
Fraser Health
Official's Role
Study Chair
Facility Information:
Facility Name
Surrey Memorial Hospital
City
Surrey
State/Province
British Columbia
ZIP/Postal Code
V3V 1Z2
Country
Canada
Facility Name
Surrey Memorial Hospital
City
Surrey
State/Province
British Columbia
ZIP/Postal Code
V3V1Z2
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Comparison Between Infant Flow SiPAP and Noninvasive NAVA in the Neonatal Intensive Care Unit

We'll reach out to this number within 24 hrs